Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zai Lab Granted Expedited China Review for Brain Cancer Medical Device

publication date: Aug 12, 2019

Shanghai's Zai Lab announced its electric field treatment for cancer, Tumor Treating Fields, was designated an Innovative Medical Device in China, which accelerates the approval process. Zai in-licensed greater China rights to the product from Novocare last year, and launched the product in Hong Kong in December as a treatment for glioblastoma multiform under the name Optune. Optune uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth and inducing cancer cell death. More details....

Stock Symbol: (NSDQ: ZLAB)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.